静脉应用氨甲环酸减少胫骨高位截骨术后失血
本研究回顾性分析156例内侧开放楔形胫骨高位截骨术(HTO),比较使用与未使用静脉氨甲环酸(TXA)患者的失血量及院内结局。TXA组总失血量显著少于对照组(372±36 mL vs 635±53 mL,平均差263 mL,95%CI 248-278,p<0.001),但两组均无输血及症状性血栓栓塞事件,疼痛评分差异小且临床意义不确定。
要点
- 静脉TXA可减少内侧开放楔形HTO术后总失血量,平均差263 mL(95%CI 248-278,p<0.001)。
- 两组均无患者接受输血,无伤口并发症(TXA组)或症状性血栓栓塞事件。
- 术后次日静息疼痛VAS评分TXA组略优,但差异小且临床意义不确定。
核心结论
- 静脉全身应用TXA可减少内侧开放楔形HTO术后失血,但鉴于本系列中未使用TXA时也无患者接受输血,且疼痛评分无临床重要差异,常规使用TXA的临床获益不确定。
- 本研究样本量太小,无法就伤口并发症或血栓栓塞事件等罕见终点做出安全性结论;需要更大样本、 preferably 随机试验来确定TXA在此场景中的重要性。
- 本研究数据有助于为此类研究的样本量计算提供信息。
研究设计与样本
- 回顾性研究,纳入2015年1月至2017年5月由单一外科医生完成的156例内侧开放楔形HTO。
- 2016年6月起所有HTO开始使用静脉TXA,此前未使用TXA;对照组89例,TXA组67例。
- 排除对照组2例同期对侧全膝关节置换及每组各1例数据缺失者,最终分析对照组86例(97%)、TXA组66例(98.5%)。
- 两组在年龄、性别、体重指数和基线血红蛋白值方面无人口学差异。
- 主要结局为总估计失血量(基于总血容量和血红蛋白下降计算);次要结局包括术后次日静息疼痛VAS评分、术后早期伤口并发症、异体输血及症状性血栓栓塞表现。
主要发现
- TXA组总失血量少于对照组(372±36 mL vs 635±53 mL,平均差263 mL,95%CI 248-278,p<0.001)。
- 术后次日静息疼痛VAS评分组间差异有利于TXA组,但差异小且不太可能具有临床重要性。
- 对照组发生2例伤口并发症(1例血肿和1例浅表伤口感染),TXA组无伤口并发症。
- 两组均无患者接受输血,均未检测到症状性血栓栓塞事件。
关键数值与推荐
- 输血决策基于预先确定的标准。
- 总估计失血量通过总血容量和血红蛋白下降值计算。
临床怎么用
- 本研究为回顾性设计,作者结论指出常规使用TXA的临床获益不确定,且需要更大样本 preferably 随机试验来确定TXA在此场景中的重要性。
局限性
- 本研究样本量太小,无法就伤口并发症或血栓栓塞事件等罕见终点做出安全性结论。
- 需要更大样本、 preferably 随机试验来确定TXA在此场景中的重要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Medial opening wedge high tibial osteotomy (HTO) entails extensive soft tissue release that may lead to substantial perioperative bleeding. Although tranexamic acid (TXA) is a well-established blood-conserving agent in total joint arthroplasty, its potential to reduce blood loss in patients undergoing HTO has not been studied extensively. QUESTIONS/PURPOSES: (1) Does TXA reduce total estimated blood loss in HTO? (2) Does TXA use in HTO affect in-hospital endpoints as measured by visual analog scale (VAS) pain scores at rest the day after surgery, wound complications in the immediate postoperative period, blood transfusions, or symptomatic deep vein thrombosis? METHODS: Between January 2015 and May 2017, a single surgeon performed 156 HTOs, all of which were done using the medial opening wedge technique. We began using intravenous TXA for all HTOs in June 2016. This left us with 89 patients who were treated during a time when no TXA was used and 67 patients who were treated when all patients received TXA. Two patients in the control group had simultaneous TKA in the contralateral leg and one patient in each group had missing data so these patients were excluded, leaving 86 (97%) patients in the control group and 66 (98.5%) in the TXA group available for analysis in this retrospective study. There were no demographic differences between the groups in terms of age, sex, body mass index, and baseline hemoglobin values. Total estimated blood loss was the primary outcome variable, which was calculated using total blood volume and decrease in hemoglobin values. Secondary outcome variables included pain VAS at rest the day after surgery, wound complications in the immediate postoperative period, allogeneic blood transfusions, and occurrence of symptomatic thromboembolic manifestations. The decision on when to transfuse was based on predetermined criteria. An orthopaedic surgeon not involved in patient care collected the patient data from electronic medical records and did chart review. RESULTS: The TXA group had less total blood loss (372 ± 36 mL versus 635 ± 53 mL, mean difference 263 mL [95% confidence interval, 248-278]; p < 0.001). Between groups, differences in VAS pain scores at rest the day after surgery favored the TXA group but were small and unlikely to be clinically important. There were two wound complications in the control group (one hematoma and one superficial wound infection) and none in the TXA group. No patients in either group received a blood transfusion, and no symptomatic thromboembolic events were detected in either group. CONCLUSIONS: This study demonstrates that the systemic administration of TXA reduces postoperative blood loss in medial opening wedge HTO; however, insofar as no transfusions were administered to patients even before the routine use of TXA in this series, and no clinically important differences in pain scores were identified, the clinical benefit of routine use of TXA in patients undergoing HTO is uncertain. Our study was too small to make safety-related claims on rare endpoints such as wound complications or thromboembolic events. Larger, and preferably randomized, trials are needed to help define whether it is important to use TXA in this setting. Our data can help inform sample size calculations for such studies. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Palanisamy JV, Das S, Moon KH, et al. Intravenous Tranexamic Acid Reduces Postoperative Blood Loss After High Tibial Osteotomy. Clin Orthop Relat Res. 2018. PMID: 29939895. doi:10.1097/CORR.0000000000000378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。